Research programme: cancer therapeutics - OXIS International

Drug Profile

Research programme: cancer therapeutics - OXIS International

Alternative Names: OXS 1950; OXS 2050; OXS 2175; OXS 4550

Latest Information Update: 12 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxis Biotech
  • Class Bispecific antibodies; Monoclonal antibodies; Small molecules
  • Mechanism of Action Cell adhesion molecule inhibitors; Cell adhesion molecule modulators; Frizzled 7 receptor antagonists; Frizzled 7 receptor modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer
  • Research Cancer

Most Recent Events

  • 12 Apr 2015 Preclinical trials in Breast cancer in USA (unspecified route)
  • 01 Apr 2015 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top